JP2011503039A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011503039A5 JP2011503039A5 JP2010532625A JP2010532625A JP2011503039A5 JP 2011503039 A5 JP2011503039 A5 JP 2011503039A5 JP 2010532625 A JP2010532625 A JP 2010532625A JP 2010532625 A JP2010532625 A JP 2010532625A JP 2011503039 A5 JP2011503039 A5 JP 2011503039A5
- Authority
- JP
- Japan
- Prior art keywords
- kit
- polynucleotide
- composition
- interferon
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 14
- 239000002157 polynucleotide Substances 0.000 claims 13
- 102000040430 polynucleotide Human genes 0.000 claims 13
- 108091033319 polynucleotide Proteins 0.000 claims 13
- 102000002227 Interferon Type I Human genes 0.000 claims 7
- 108010014726 Interferon Type I Proteins 0.000 claims 7
- 108010037274 Member 9 Tumor Necrosis Factor Receptor Superfamily Proteins 0.000 claims 6
- 102000011769 Member 9 Tumor Necrosis Factor Receptor Superfamily Human genes 0.000 claims 6
- 239000003446 ligand Substances 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 239000000018 receptor agonist Substances 0.000 claims 5
- 229940044601 receptor agonist Drugs 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 108010047761 Interferon-alpha Proteins 0.000 claims 3
- 102000006992 Interferon-alpha Human genes 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- -1 IFN-α4 Proteins 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 101000999354 Bos taurus Interferon alpha-H Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 1
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 229960001388 interferon-beta Drugs 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200702961A ES2336873B1 (es) | 2007-11-07 | 2007-11-07 | Composicion farmaceutica para el tratamiento de cancer. |
| PCT/ES2008/000693 WO2009060112A1 (es) | 2007-11-07 | 2008-11-07 | Composición farmacéutica para el tratamiento de cáncer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011503039A JP2011503039A (ja) | 2011-01-27 |
| JP2011503039A5 true JP2011503039A5 (https=) | 2011-12-22 |
Family
ID=40351964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010532625A Pending JP2011503039A (ja) | 2007-11-07 | 2008-11-07 | 癌治療用医薬組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110059045A1 (https=) |
| EP (1) | EP2223701A1 (https=) |
| JP (1) | JP2011503039A (https=) |
| CN (1) | CN101951955A (https=) |
| AU (1) | AU2008324056A1 (https=) |
| BR (1) | BRPI0820351A2 (https=) |
| CA (1) | CA2705105A1 (https=) |
| ES (1) | ES2336873B1 (https=) |
| MX (1) | MX2010005086A (https=) |
| RU (1) | RU2010122934A (https=) |
| WO (1) | WO2009060112A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014005091A2 (pt) | 2011-09-05 | 2017-06-13 | Beijing Hanmi Pharmaceutical Co Ltd | composição farmacêutica para o tratamento do câncer compreendendo conjugado de interferon alfa |
| CN104684923B (zh) | 2012-07-13 | 2018-09-28 | 株式会社新日本科学 | 手性核酸佐剂 |
| TWI718086B (zh) * | 2013-01-07 | 2021-02-11 | 英屬維爾京群島商遠東超級實驗室有限公司 | 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物 |
| EP3082839A4 (en) * | 2013-12-20 | 2017-08-09 | National University of Singapore | Differentiation therapy with cd137 ligand agonists |
| WO2016156291A1 (en) * | 2015-03-31 | 2016-10-06 | F. Hoffmann-La Roche Ag | Antigen binding molecules comprising a trimeric tnf family ligand |
| CN111511762B (zh) | 2017-08-21 | 2025-05-06 | 天演药业公司 | 抗cd137分子及其用途 |
| WO2019104716A1 (en) * | 2017-12-01 | 2019-06-06 | Adagene Inc. | Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040197312A1 (en) * | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
| WO2006088447A1 (en) * | 2005-02-15 | 2006-08-24 | Gtc Biotherapeutics, Inc. | An anti-cd137 antibody as an agent in the treatement of cancer and glycosylation variants thereof |
| KR20080068089A (ko) * | 2005-10-21 | 2008-07-22 | 지티씨바이오쎄라퓨틱스,인크. | 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및사용 방법 |
-
2007
- 2007-11-07 ES ES200702961A patent/ES2336873B1/es not_active Withdrawn - After Issue
-
2008
- 2008-11-07 MX MX2010005086A patent/MX2010005086A/es not_active Application Discontinuation
- 2008-11-07 AU AU2008324056A patent/AU2008324056A1/en not_active Abandoned
- 2008-11-07 EP EP08846883A patent/EP2223701A1/en not_active Withdrawn
- 2008-11-07 CA CA2705105A patent/CA2705105A1/en not_active Abandoned
- 2008-11-07 BR BRPI0820351A patent/BRPI0820351A2/pt not_active IP Right Cessation
- 2008-11-07 CN CN2008801242034A patent/CN101951955A/zh active Pending
- 2008-11-07 RU RU2010122934/15A patent/RU2010122934A/ru not_active Application Discontinuation
- 2008-11-07 JP JP2010532625A patent/JP2011503039A/ja active Pending
- 2008-11-07 WO PCT/ES2008/000693 patent/WO2009060112A1/es not_active Ceased
- 2008-11-07 US US12/741,304 patent/US20110059045A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011503039A5 (https=) | ||
| JP2008507536A5 (https=) | ||
| Ciardiello et al. | Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225 | |
| Arnaldez et al. | Targeting the insulin growth factor receptor 1 | |
| JP2013507439A5 (https=) | ||
| JP2012067116A5 (https=) | ||
| RU2010122934A (ru) | Фармацевтическая композиция для лечения злокачественных опухолей | |
| JP2020510662A5 (https=) | ||
| JP2009505676A5 (https=) | ||
| JP2015512860A5 (https=) | ||
| KR101993963B1 (ko) | 항 종양제 및 항 종양 효과 증강제 | |
| JP2012034692A5 (https=) | ||
| JP2008500815A5 (https=) | ||
| JP2017506217A5 (https=) | ||
| IL292193B2 (en) | Anti-b7-h1 antibodies for treating tumors | |
| JP2013509429A5 (https=) | ||
| ME02806B (me) | Protutijela protiv csf-1r | |
| JP2013503202A5 (https=) | ||
| JP2006524246A5 (https=) | ||
| JP2017514800A5 (https=) | ||
| JP2010502759A5 (https=) | ||
| JP2014507412A5 (https=) | ||
| JP2014523398A5 (https=) | ||
| JP2009539994A5 (https=) | ||
| JP2019038796A5 (https=) |